EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants

Alessandra Cipriano, Ram P Kapil, Mingyan Zhou, Manjunath S Shet, Garth T Whiteside, Sandra K Willsie, Stephen C Harris

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1394 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Alessandra Cipriano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Imbrium Therapeutics, Stamford, CT, USA. Hauptthemen laut MEDLINE: Cross-Over Studies, Healthy Volunteers, Area Under Curve. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sunobinop is an investigational, potent, selective partial agonist at the nociceptin/orphanin FQ peptide receptor in vitro. Three phase 1 studies were conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating single‐ and multiple‐dose administration of sunobinop in healthy participants. Study 1 was a randomized, double‐blind, placebo‐controlled, single‐ascending dose study. Study 2 was a randomized, double‐blind, placebo‐controlled, multiple‐ascending dose study. Study 3 was a randomized, open‐label, single‐dose, 4‐way crossover study of oral and sublingual sunobinop comparing morning (AM) and bedtime (PM) administration. Seventy participants were included. Systemic exposure (peak plasma concentration [C max ], area under the plasma concentration‐time curve from time 0 to the time of last quantifiable concentration [AUC 0‐t ], and area under the plasma concentration–time curve from time 0 extrapolated to infinity [AUC inf ]) of sunobinop was characterized by dose proportionality from 0.6 to 2 mg and increased less than proportionally from 3 to 30 mg. The PKs of sunobinop were similar, regardless of AM or PM administration, for both the oral and sublingual formulations. The majority of absorbed sunobinop was excreted unchanged in the urine within 8 hours of dosing, thereby showing rapid elimination with no appreciable accumulation following 14 consecutive days of once‐daily dosing and suggesting exclusive renal elimination. Most treatment‐emergent adverse events (TEAEs) were mild in severity; 1 severe TEAE occurred and all TEAEs resolved by the end of the studies. Sunobinop was generally well‐tolerated and safe across the range of doses evaluated and presents a clinical profile suitable for continued development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cross-Over StudiesHealthy VolunteersArea Under CurveHumansMaleAdultDouble-Blind MethodFemaleMiddle AgedYoung AdultAdministration, OralDose-Response Relationship, DrugAdministration, SublingualDrug Administration ScheduleNociceptin ReceptorReceptors, OpioidAdolescentMorphinansNaltrexone

Stichwörter der Autor:innen

NOPORL1nociceptin/orphanin FQpharmacokineticssafetysunobinop

Substanzen

Nociceptin ReceptorReceptors, OpioidOPRL1 protein, human3-carboxamido-4-hydroxynaltrexoneMorphinansNaltrexone

Autor:innen und Institutionen

  • Imbrium Therapeutics, Stamford, CT, USA.
  • Pharmaceutical Research Associates, Raleigh, NC, USA.

Zitieren

APA

Cipriano, A., Kapil, R. P., Zhou, M., Shet, M. S., Whiteside, G. T., Willsie, S. K., & Harris, S. C. (2024). Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1394

Vancouver

Cipriano A, Kapil RP, Zhou M, Shet MS, Whiteside GT, Willsie SK, et al. Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1394

BibTeX
@article{Cipriano2024,
  author = {Cipriano, Alessandra and Kapil, Ram P and Zhou, Mingyan and Shet, Manjunath S and Whiteside, Garth T and Willsie, Sandra K and Harris, Stephen C},
  title = {Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1394}
}
Kostenlos starten →